Joseph Wu
Director of the Stanford Cardiovascular Institute
Greenstone Biosciences
Greenstone Biosciences provides human iPSC-derived cells and 3D organoids to support New Approach Methods (NAMs) in drug discovery. The company offers custom cell engineering, high-throughput screening services, and proprietary AI platforms for preclinical validation. This integrated approach aims to accelerate the development of safer and more effective therapeutic candidates.
- Artificial Intelligence
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$10.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional drug discovery processes are inefficient and time-consuming, often failing to accurately identify effective therapeutic compounds early in development. This results in increased costs and delays in bringing new treatments to patients.
Solution
Greenstone Biosciences accelerates drug discovery by integrating artificial intelligence (AI), genomics, and human induced pluripotent stem cells (hiPSCs). Their AI-hiPSC platform enables a more efficient and precise approach to identifying potential therapeutic compounds. By leveraging a comprehensive iPSC biobank and computational biology, Greenstone aims to transform drug discovery, expediting the development of effective therapies. The platform facilitates multiscale drug screening, integrating human iPSC models, tissue engineering, animal models, in silico simulations, and multiomics to identify therapeutic targets.
Target Audience
Greenstone Biosciences primarily serves pharmaceutical companies, biotechnology firms, and academic research institutions seeking to improve the efficiency and accuracy of their drug discovery efforts.
Features
- AI-driven platform for identifying and validating therapeutic compounds
- Large hiPSC biobank for disease modeling and drug screening
- Multiscale drug screening integrating iPSC-derived cells, 3D-engineered tissues, and animal models
- ADMET.AI tool for predicting absorption, distribution, metabolism, excretion, and toxicity of drug candidates
- Capability to identify novel therapeutic targets and mechanisms of action
- Application of genomics and computational biology to enhance drug discovery